ClinicalTrials.gg

Program

chiauranib

Also written as “Chiauranib”.

Its studies are mostly in Small Cell Lung Carcinoma · Ovarian Neoplasms · Lymphoma, Non-Hodgkin · Sarcoma · Triple Negative Breast Neoplasms, led by Chipscreen Biosciences.

Furthest: phase 3, since Mar 29, 202115 company-led studies, 4 open or runningNext primary completion: Feb 28, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Chipscreen Biosciences154 open or runningphase 3since Mar 29, 2021Apr 22, 2014Feb 28, 2027phase 2 · NCT06492915

Also a collaborator on its studies: h-j-cro-international-inc.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 1 study since Apr 22, 2014.

  1. Mar 1, 2017Phase 1 study in Lymphoma, Non-HodgkinNCT03074825 · 5 enrolled · China
  2. May 22, 2017Phase 2 study in Ovarian NeoplasmsNCT03166891 · 25 enrolled · China
  3. Jul 10, 2017Phase 1 study in Small Cell Lung CarcinomaNCT03216343 · 48 enrolled · China
  4. Aug 4, 2017Phase 2 study in Carcinoma, HepatocellularNCT03245190 · 27 enrolled · China
  5. May 30, 2019Phase 2 study in Lymphoma, Non-HodgkinNCT03974243 · 9 enrolled · China
  6. Mar 29, 2021Phase 3 study in Small Cell Lung CarcinomaNCT04830813 · 184 enrolled · China
  7. Jun 3, 2021Phase 3 study in Ovarian NeoplasmsNCT04921527 · 454 planned · China
  8. Jan 26, 2022Phase 2 study in Small Cell Lung CarcinomaNCT05271292 · 36 planned · United States
  9. Apr 14, 2022Phase 1 study in Healthy VolunteersNCT05346601 · 16 enrolled · China
  10. Apr 14, 2022Phase 2 study in Triple Negative Breast NeoplasmsNCT05336721 · 9 enrolled · China
  11. May 4, 2022No phase study in Small Cell Lung CarcinomaNCT05371899 · 6 enrolled · China
  12. Aug 9, 2022Phase 2 study in SarcomaNCT05497843 · 40 enrolled · China
  13. Jun 27, 2024Phase 2 study in Pancreatic Ductal AdenocarcinomaNCT06492915 · 42 enrolled · China
  14. Feb 25, 2026Phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07445295 · 558 planned · China

Ahead

  1. Feb 28, 2027Primary completion: phase 2 study in Pancreatic Ductal AdenocarcinomaNCT06492915
  2. Jun 30, 2028Primary completion: phase 3 study in Metastatic Pancreatic Ductal AdenocarcinomaNCT07445295

TargetBeta

“Serine/threonine-protein kinase Aurora-B inhibitor; Vascular endothelial growth factor receptor inhibitor”ChEMBL 37, by rule

Studies

All 15 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07445295Metastatic Pancreatic Ductal Adenocarcinoma · China3Not yet recruitingJun 30, 2028558
NCT06492915Pancreatic Ductal Adenocarcinoma · China2Active, not recruitingFeb 28, 202742
NCT05497843Sarcoma · China2CompletedJan 3, 202540
NCT05371899Small Cell Lung Carcinoma · China–CompletedMar 18, 20246
NCT05346601Healthy Volunteers · China1CompletedJun 28, 202216
NCT05336721Triple Negative Breast Neoplasms · China2TerminatedOct 31, 20249
NCT05271292Small Cell Lung Carcinoma · United States2RecruitingMar 202536
NCT04921527Ovarian Neoplasms · China3RecruitingDec 31, 2024454
NCT04830813Small Cell Lung Carcinoma · China3CompletedApr 1, 2024184
NCT03974243Lymphoma, Non-Hodgkin · China2CompletedDec 31, 20219
NCT03245190Carcinoma, Hepatocellular · China2CompletedNov 1, 201927
NCT03216343Small Cell Lung Carcinoma · China1CompletedNov 4, 202248
NCT03166891Ovarian Neoplasms · China2CompletedMar 20, 201925
NCT03074825Lymphoma, Non-Hodgkin · China1TerminatedAug 15, 20175
NCT02122809Solid Tumors · China1CompletedApr 201618

How it is read

Names in the registry

  • “Chiauranib”, 14 entries
  • “chiauranib”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.